Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Halozyme Therapeutic (NQ: HALO ) 56.98 +0.34 (+0.60%) Streaming Delayed Price Updated: 9:46 AM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Halozyme Therapeutic < Previous 1 2 3 4 5 6 7 8 9 Next > NASDAQ:HALO is showing good growth, while it is not too expensive. September 19, 2024 Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. Via Chartmill NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. September 19, 2024 HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. Via Chartmill Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire (HALO) - Analyzing Halozyme Therapeutics's Short Interest September 13, 2024 Via Benzinga Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. September 13, 2024 HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. Via Chartmill Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know September 13, 2024 Via Benzinga NASDAQ:HALO is not too expensive for the growth it is showing. August 29, 2024 NASDAQ:HALO is showing good growth, while it is not too expensive. Via Chartmill Top 2 Health Care Stocks That May Plunge In August August 26, 2024 Via Benzinga How Is The Market Feeling About Halozyme Therapeutics? August 20, 2024 Via Benzinga NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. August 28, 2024 HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying. Via Chartmill Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review August 09, 2024 After Monday's panicked global sell-off, markets have calmed down. Via Investor's Business Daily Looking for growth without the hefty price tag? Consider NASDAQ:HALO. August 08, 2024 Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. Via Chartmill Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. August 08, 2024 Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace (HALO) - Analyzing Halozyme Therapeutics's Short Interest August 01, 2024 Via Benzinga Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics August 01, 2024 Via Benzinga Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. July 22, 2024 There are signs that NASDAQ:HALO may be ready to breakout. Via Chartmill Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts August 06, 2024 Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. Via Investor's Business Daily Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 August 06, 2024 On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. Via Investor's Business Daily NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. August 05, 2024 When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. Via Chartmill 3 Biotech Stocks on Track for 50% Returns (or More) by 2028 August 04, 2024 Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! Via InvestorPlace Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark July 26, 2024 On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. Via Investor's Business Daily Beam Therapeutics Stock Earns RS Rating Jump To 85 July 24, 2024 On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. Via Investor's Business Daily NASDAQ:HALO is showing good growth, while it is not too expensive. July 18, 2024 HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. Via Chartmill What 13 Analyst Ratings Have To Say About Halozyme Therapeutics July 16, 2024 Via Benzinga NASDAQ:HALO qualifies as a high growth stock and is consolidating. July 15, 2024 HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. Via Chartmill 3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition July 18, 2024 These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. Via InvestorPlace Biotech Arvinas Stock Earns 82 RS Rating July 17, 2024 The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. Via Investor's Business Daily Denali Therapeutics Stock Gets Technical Rating Upgrade July 16, 2024 Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Via Investor's Business Daily 3 Biotech Stocks to Buy Now: Q3 Edition July 15, 2024 Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.